FibroBiologics, Inc. 8-K

What Happened FibroBiologics, Inc. (FBLG) filed an 8-K reporting that on May 1, 2026 it entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of its common stock from time to time. On May 5, 2026 the company filed an updated prospectus supplement increasing the maximum aggregate offering to $7,500,000. The shares would be issued under the company’s existing Form S-3 shelf registration (Registration No. 333-284663, filed Feb 3, 2025; declared effective Feb 10, 2025). To date, 71,830 shares have been sold under the agreement.

Key Details

• ATM Sales Agreement date: May 1, 2026 with H.C. Wainwright & Co., LLC.
• Updated prospectus supplement filed: May 5, 2026, raising the maximum to $7,500,000.
• Shelf registration: Form S-3 (Reg. No. 333-284663), filed Feb 3, 2025 and effective Feb 10, 2025.
• Shares sold so far under the agreement: 71,830 shares; legal opinion and consent from counsel (Sichenzia Ross Ference Carmel LLP) filed as exhibits.

Why It Matters This ATM facility gives FibroBiologics a flexible way to raise up to $7.5M of capital by selling common stock over time, which can help fund operations or development without a single large equity offering. Any future sales will increase the company’s shares outstanding and may dilute existing shareholders; the filing also makes clear there is no guarantee of sales and sales will occur only as permitted under securities laws. The update and counsel opinion are procedural steps that enable the company to use the ATM program when management chooses.